Navigation Links
Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
Date:3/26/2012

 

p=0.59

p=0.42Responder Analysis 

 

 

 "Much Improved or Very Much Improved" 

 

 

   Clinical Global Impression-Tardive Dyskinesia

n/a

52%

65%

60%  Patient Global Impression of Change

n/a

39%

53%

60%  Excluding Single Site Baseline(mean)Placebo12.5mg50mgAbnormal Involuntary Movement Scale (LS Means)14.9

10.3

9.9

6.1 

 

 

p=0.68

p=0.002Responder Analysis end of Treatment 

 

 

 "Much Improved or Very Much Improved" 

 

 

 Clinical Global Impression-Tardive Dyskinesia

n/a

46%

67%

80%Patient Global Impression of Change

n/a

38%

62%

80%Safety ProfileNBI-98854 was generally safe and well tolerated; the frequency of treatment-emergent adverse events was 17% during the placebo period and 24% and 32% in the 12.5mg and 50mg treatment periods, respectively. There were no serious adverse events during the treatment period. The most common adverse event was headache and one subject in the 50mg group discontinued due to akathisia. The underlying psychiatric state of subjects was monitored using the Brief Psychiatric Ratings Scale (BPRS) and shown to be stable or improved across study groups declining from 32 at baseline to 28 at the end of the study. There were no drug-drug interactions identified in subjects who were utilizing a range of psychotropic and other concomitant medications.

"While not ideal, this study served its primary purpose of informing the larger Phase IIb studies. The 50mg once-daily dose of NBI-98854 provided tardive dyskinesia sufferers with a remarkable improvement of symptoms, coupled with an excellent
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
2. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
3. Neurocrine Mourns the Passing of Founder and Board Member Wylie Vale, Ph.D.
4. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
6. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
8. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)... N.C. , May 16, 2013  Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... obesity and,complications arising from popular aesthetic surgical procedure, ... study,investigating the relationship between complications of body contouring,surgery ... in the occurrence of,such complications with worsening degree ... the July/August 2008 issue of the Aesthetic Surgery,Journal, ...
... MOORESVILLE, N.C., July 30 Anpath Group, Inc.,(OTC ... owned,subsidiary, EnviroSystems, Inc. (ESI) announced that its EnviroTru(R),disinfectant ... Department of,Management Services (DMS) in the State of ... of Green, LLC(TM) ( http://www.aworldofgreen.com ),worked ...
Cached Medicine Technology:Body Contouring Surgery Risk Rises with Increased Body Mass Index 2Body Contouring Surgery Risk Rises with Increased Body Mass Index 3Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:5/19/2013)... Los Angeles, California (PRWEB) May 19, 2013 ... “The Best Body Firmers” many people are self-conscious about the ... becomes an option when diet and exercise fail to ... treatments that may appeal to those looking to get the ... the article is an effective mini-overview,” says Dr. Simon Ourian, ...
(Date:5/19/2013)... York (PRWEB) May 19, 2013 ... a federal litigation now underway in U.S. District Court, ... Management Order dated May 3rd, the Court has modified ... Pool to eight cases rather than four. The next ... for Thursday, May 23rd. (In re: Actos Product Liability ...
(Date:5/19/2013)... Corpus Christi, TX (PRWEB) May 19, 2013 ... home security systems companies. Homeowners who are considering ... options and services of the nation's leading security system ... security systems reviews the best DIY home security ... results. Every year 6Webs.com reviews dozens of home security ...
(Date:5/19/2013)... 19, 2013 Americans live closer to ... newest American Veterinary Medical Association (AVMA) U.S. Pet Ownership ... owners consider their dog a member of the family, ... as much five years earlier. , According to the ... the national income dedicated to pets has increased every ...
(Date:5/19/2013)... Angeles (PRWEB) May 19, 2013 Yeast infections ... can appear in sensitive areas of the human body. A ... Yeastrol. This new formula provides a unique method of application ... new spray solution is now provided to men and women ... is naturally absorbed in the body through food and is ...
Breaking Medicine News(10 mins):Health News:Body Firming – The Hottest Treatments Available 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2
... the combination of just two genes, according to a new study ... of Clinical Endocrinology and Metabolism this week, identifies one gene on ... height in men. These genes may also help explain why men ... of both of these genes you will be taller than a ...
... that, too much sleep and snoring could put you at ... of Buffalo, New York, have found that sleeping more than ... day can damage your health. Experts say this means snoring ... seriously.// ,Dr David Smithard, Consultant in Stroke Medicine ...
... Doctors from England are trialling the first long-acting male contraceptive ... every three months, is a combination of hormones. ,In ... then a pellet of the male hormone testosterone is placed ... from the Royal Kings Hospital in UK says the technique ...
... exercise is a better indicator of heart disease risk than ... risk of heart disease and stroke. Normally, doctors measure blood ... But researchers at University of San Diego now show that ... be treated and detected.// ,They measured the blood pressure ...
... new test really helps detect heart problems. A test for cardiac ... are really having a heart attack. Only 10 to 15 per ... chest pain are actually having a heart attack. Other causes of ... test may take several hours and maybe a formal hospital admission ...
... found that genes contribute to the risk of chronic ... (COPD), the name given to chronic bronchitis and emphysema ... shortness of breath. It's linked with gradual destruction of ... the problem.// ,However, not all smokers go ...
Cached Medicine News:
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
... complete range of needle sizes to ensure that ... be obtained with any skin type, quickly, easily ... of needle diameters enable users to obtain blood ... damage. This makes it easier to comply with ...
Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
Medicine Products: